Many solid tumors, including non-small cell lung cancers (NSCLCs), are characterized by heterogenous expression of p53 protein in the neoplastic cells. To analyse the molecular implications of this ®nding, we examined topographic distribution of p53 mutations using in situ polymerase chain reaction (PCR) in primary NSCLCs, showing distinct patterns of variable p53 overexpression by immunohistochemistry. Unique sets of primers for each mutation were designed, and optimal PCR conditions were determined by standard PCR using DNA from cloned mutants or cell lines established from these tumors. All tumor cell nuclei, regardless of the status of p53 overexpression, demonstrated homogeneous distribution of mutant p53 with speci®c primers, indicating that only subgroups of the mutated cells overexpressed p53 protein. In situ reverse transcription (RT) ± PCR was applied to detect mutant mRNA in the individual tumor cells using speci®c primers. We found that in each case the distribution of mutant p53 mRNA coincided with that of immunohistochemical overexpression of p53 protein. Our results suggest that the regulation of mutant p53 expression, but not the genotype, is heterogeneous in the neoplastic cells. The topographic genomapping of p53 in NSCLC using in situ PCR provides a novel approach to view molecular mechanisms of lung carcinogenesis. Oncogene (2001) 20, 2579 ± 2586.
Introduction
Alterations in the tumor suppressor gene p53 are frequent events in non-small cell lung cancers (NSCLC), and may have prognostic importance (Takahashi et al., 1989; Mitsudomi et al., 1992; Horio et al., 1993) . The main mechanism of action involves a point mutation in one allele and complete loss of the second allele (Greenblatt et al., 1994) .
Mutant p53 has a longer half-life than wild p53 (Oren et al., 1981; Reihsaus et al., 1990) and we have previously established a correlation with the overexpression of p53 protein by immunohistochemistry and the presence of mutations in lung cancer cell lines . In lung tumors, we noted marked variability in the immunohistochemical staining patterns of p53 protein with two major patterns (Ebina et al., 1994) . One revealed focal positivity throughout the tumor at random locations giving a spotty appearance, and another consisted of positive staining along the periphery of the tumor. Interestingly, there was no correlation between the expression of p53 and proliferating cell nuclear antigen (PCNA) in the tumors, suggesting that the variability was perhaps not due to cell cycle dependent regulation (Prives, 1998) .
There are two likely explanations for the heterogeneous distribution patterns of p53 immunoreactivity in tumors: (i) polyclonal expansion of the tumor cells with dierent p53 status, or (ii) dierences in the regulation of mutant p53 expression through transcriptional activity or stability in tumor cells while they may all carry the same mutation. To begin to elucidate the underlying mechanisms it was necessary to assess the mRNA levels of mutant and wild-type p53 in individual cells. Thus we developed a novel method to detect speci®c p53 mutations in tissue sections by performing in situ polymerase chain reaction (PCR) on a glass slide, selectively amplifying the DNA fragments of interest (Hasse et al., 1990; MartõÂ nez et al., 1995) . The selection of primers was based on the two base-pair mismatch method (Cha et al., 1992) . We also applied in situ reverse transcription (RT) ± PCR to detect mutant mRNAs of p53. The reaction of in situ RT ± PCR using mutant speci®c primers would be able to reveal both mutant cDNA fragments ampli®ed within the cytoplasm and mutant DNA fragments ampli®ed within the nucleus in a single tumor cell at the same time.
These techniques allowed us to visualize the same p53 mutation in all tumor cells, while the levels of mutant mRNA were variable. Moreover, there was a correlation between the expression of mutant mRNA and immunohistochemical staining for p53. Our ®ndings support the concept that heterogeneous distribution patterns of p53 immunoreactivity in NSCLCs resulted from regulation of mutant p53 expression rather than genotypic dierences in tumor cells.
Results and Discussion
Diffuse pattern of p53 overexpression and a point mutation
The specimen (Case 1) was a right lower lobe lung mass from a 55-year-old 30 pack year smoker. Histologically it was a poorly dierentiated NSCLC which by immunohistochemistry revealed low level of diusely distributed nuclear staining indicating p53 overexpression in most of the tumor cells. No Mdm2 expression was detected. A point mutation at codon 47 of p53 (CCG to TCG) was identi®ed by DNA sequencing of the microdissected material ( Figure 1a ). This coincided with the mutation of the cell line NCI ± H1373 which was established from the pericardial¯uid of the same patient 18 months after the resection of the primary lung cancer. We selected an optimal PCR condition for each tumor with its individually designed primers including mutant speci®c (Muts, Figure 2a ), wild-type speci®c (WTs), common (Com) primers, and omission of primers (0).
In situ PCR of the NCI ± H1373 cell pellet, using Muts primers, demonstrated speci®c nuclear staining in over 90% cells (Figure 3a) , whereas less than 1% faintly positive cells were seen in NCI ± H460, which has a wildtype p53 gene, by these primers even after 35 cycles of PCR. As expected, when Wts primers were used, NCI ± H1373 cells were negative (Figure 3b) , while NCI ± H460 were intensely positive. In the Case 1 tumor specimen, all tumor cells were ampli®ed by in situ PCR with the Muts primers (Figure 3d ). The amplicons obtained with Muts primers were con®rmed by Southern blotting (88 base-pairs, Figure 3c ). No tumor cells were positive with WTs primers although non-malignant cells, such as alveolar cells or macrophages in the normal appearing lung tissue surrounding the tumor were positive with this set of primers ( Figure 3e ). As a positive control, in situ PCR using common (Com) primers revealed that all nuclei of both tumor and nonneoplastic cells were reactive (Figure 3f ). When primers were omitted, as a negative control, most of the nuclei on the section remained negative, with the exception of rare cells conceivably undergoing apoptosis or DNA repair which were positive (Figure 3g ). Scattered cells among unremarkable bronchiolar epithelial cells which showed p53 overexpression by immunohistochemistry ( Figure  3h ), were also positive with Muts primers (Figure 3i ). These cells were too few for us to resolve if they represented tumor cells from the near-by focus of tumor or potentially premalignant airway epithelial cells.
The reactions by the four sets of individually designed primers for each mutation do not only yield speci®city, but potentially address the question whether a single p53-mutant cell reveals a loss of heterozygosity (LOH). The Case 1 tumor specimen indicated the presence of only mutant p53, because no ampli®cation was observed with wild-type speci®c primers in tumors. The ability to document LOH at the cellular level is another potentially important application.
Peripheral distribution of the p53 overexpressing tumor cells and a point mutation Case 2 tumor specimen was obtained from a right lower lobe tumor mass of a 66-year-old patient with severe chronic pulmonary emphysema. Histologically, it was a moderately dierentiated papillary adenocarcinoma which demonstrated focal p53 overexpression by immunohistochemistry, composed of strongly stained nuclei distributed over the peripheral areas of the tumor, while most of the tumor cells were positive for proliferating cell nuclear antigen (PCNA) (Figure 4a ). No Mdm2 expression was found in tumor cells. DNA sequencing revealed a point mutation of p53 at codon 277, TGT to TTT (Figure 1b) . While the tumor cells (Figure 2d ), on the contrary, strong reaction was seen only in the nuclei of the normal cells surrounding the tumor (Figure 4c ). Moreover, using in situ RT ± PCR, cDNA fragments which were reverse transcribed from the mutant p53 mRNA were ampli®ed speci®cally with the Muts cDNA primers (sense in exon 7; 5'-GGCCCATCCT-CACCATCA-3' and antisense in exon 8; 5'-TGCGCCGGTCTCTCCCAGGGAAC-3') resulting in cytoplasmic staining indicating the presence of this speci®c p53 point mutation at the mRNA level ( Figure  4d ). The signal was detected exclusively in the periphery of the tumor coinciding with the distribution of p53 protein-positive nuclei by immunohistochemistry. Interestingly, our in situ RT ± PCR without DNase treatment clearly revealed both mutant DNA in the nuclei and mutant cDNA in the cytoplasm of the appropriate cells (Figure 4d ). The tumor cells without overexpression of p53 revealed mutant p53 without detectable mutant p53 mRNA by in situ RT ± PCR using Muts primers ( Figure 4e ).
Our current data support calling tumors positive for p53 when there is only focal overexpression of p53 staining, and, moreover, these results clearly demonstrate how immunohistochemical studies of small biopsies may yield misleading conclusions, as staining for p53 may be negative while molecular analysis including in situ PCR would reveal the possible genetic change in the negative cells. The heterogenous staining pattern of these tumors would have been predicted to re¯ect a heterogenous pattern of gene mutation. This is clearly not the case and strongly suggests an interaction potentially with a variety of transcription factors which may control p53 expression (Kirch et al., 1999; Schreiber et al., 1999) . The homogenous distribution of mutations of the p53 gene in NSCLCs does suggest that the alteration occurred before the clonal expansion of these tumors, which we have recently reported in adenosquamous carcinoma of the lung (Kanazawa et al., 2000) . Schema of the speci®c primers for each mutation-site and standard PCR reactions by the primer sets. The primers for wild-type speci®c (WTs), mutant speci®c (Muts), and common DNA fragments (Com) of each tumor, illustrated in schematic drawings, and the standard PCR reactions by these primer sets are shown in a ± c (Case 1), d and e (Case 2), f and g (Case 3). Control DNA is human genomic DNA with wild-type p53. Mutant DNAs extracted from the tumor tissues were cloned and ampli®ed using these primer sets. The cell lines, NCI ± H1373 and NCI ± H727, both of which were established from the tumor tissues of Cases 1 and 3, respectively, were also used as mutation controls. (b) The test reactions for selecting optimal PCR conditions (2.5 mM Mg 2+ , pH 10.0, with an annealing temperature of 618C) for Muts primers in Case 1 are shown. W; wild-type p53 DNA and M; mutant p53 DNA. The PCR reactions without primers were always compared as negative control (0 in c, e, and g) Oncogene Topography of mutant p53 in non-small cell lung cancer M Ebina et al Scattered foci of p53 overexpression and a nine base-pair duplication Case 3 specimen was obtained from a 65-year-old, 60 pack-year smoker who underwent a surgical resection for a right upper lobe lung mass which was found to extend to the pleura. Histologically the tumor was an atypical carcinoid which revealed scattered clusters of cells with p53 positive nuclei by immunohistochemistry (Figure 5a ). The tumor was negative by Mdm2 staining. Our molecular analysis of the primary tumor identi®ed a nine base-pair duplication in exon 5 of the p53 gene (Figure 1c ). This abnormality was also present in the cell line NCI ± H727 derived from this primary . In this case, because designing Wts primers was impossible, only two sets of primers were synthesized. The Case 3 tumor, which demonstrated p53 protein overexpression in a limited number of cells, was found to have the same mutation (nine base-pair duplication) throughout all the tumor cells, as indicated by ampli®cation with Muts primers (Figure 2f ) during in situ PCR (Figure 5b ). This observation was con®rmed by PCR ± SSCP, which revealed similar shifted bands in both the p53 positive and the negative immunoreactive areas which were microdissected for this analysis (Figure 5e ). In non-malignant lung tissue distant from the primary tumor, foci of Type II cell hyperplasia revealed no p53 overexpression by immunohistochemistry, no reaction with mutant speci®c (Muts) primers and no shifted band by PCR ± SSCP, further con®rming the reliability of the mutant speci®c reaction (data not shown). By in situ RT ± PCR, a variable pattern was observed consisting of dark Common primers reacted with both wild-type and mutant p53 (f), while no ampli®cation was seen without primers (g). Several nuclei in the lining of bronchiolar epithelium were found to have p53 mutation by in situ PCR (h, arrows, 6200). Same cells also revealed p53 overexpression by immunohistochemistry (i, arrows; immunoperoxidase stain, 6200). t; tumor Recent studies from multiple laboratories have demonstrated posttranslational mechanisms by which the wild-type p53 protein half life is extended including through Mdm2 interactions and possible phosphorylation (Prives, 1998) . This leads to a disproportionate amount of p53 protein when compared to mRNA. Thus, it could be anticipated that one should ®nd tumors with p53 immunoreactivity, low amounts of mRNA and a wild-type gene. Indeed, the pattern of p53 immunoreactivity could be heterogenous as the abnormalities such as hypoxia, or genotoxic stress may be present only in certain areas of the tumor. However, we examined tumors which displayed mutant p53 which by the virtue of its mutation has an extended protein half life. Our approach using RT ± PCR may also help resolve discrepancies between the immunohistochemical studies and molecular analyses of p53 in human lung cancers using whole tumor DNA or mRNA (Brambilla et al., 1993) .
In summary, we describe an assay to examine the consequences of p53 mutations for gene expression in lung carcinogenesis at the cellular level. The somewhat unexpected ®nding of a correlation of the mutant p53 mRNA and protein expression in tumor cells underscores the importance of novel complementary techniques that may extend beyond microdissection (Park et al., 1999) . Potential applications of in situ methods include genetic analyses in many clinical settings employing existing, archival material (Nuovo et al., 1999) .
Materials and methods

Tumors and cell lines
Surgically resected specimens of the primary NSCLC tumors (Cases 1 ± 3) and corresponding lung cancer cell lines NCI ± H1373 and NCI ± H727 were part of a prospective clinical trial of the patients with any stage or histologic subtype of pathologically con®rmed NSCLC with an Eastern Cooperative Oncology Group performance status of three or better (at least partially ambulatory) who were entered into the study at the NCI ± Navy Medical Oncology Branch as previously described (Shaw et al., 1996) . In addition, we used a well characterized NCI ± H460 lung cancer cell line (NCI ± Navy Medical Oncology Branch, Bethesda, MD, USA) as a control for wild-type p53 (Takahashi et al., 1989) . All material used in the current study was derived from investigations which were performed after approval by local institutional review boards.
Tumor specimens were ®xed with 10% formalin and embedded in paran according to routine procedures. To simulate the conditions of tumor specimens, pellets of freshly grown cell lines were ®xed for 2 h in 4% paraformaldehyde, washed in PBS, resuspended in 1 ml of 2% NuSieve low melting-point agarose (NuSieve R , FMC BioProducts, Rockland, ME, USA), allowed to solidify and embedded in paran (Takahashi et al., 1989) . Sections from the paranembedded cell pellets were used to test the speci®city of in situ PCR reactions.
Immunohistochemistry
Following antigen retrieval, p53 immunostaining was performed using the mouse monoclonal antibody DO-7 against human p53 (Dako Corporation, Carpinteria, CA, USA) at 4.8 mg/ml, and avidin-biotinylated peroxidase method with Vectastain kit (Vector Laboratories, Burlingame, CA, USA) as previously described (Ebina et al., 1994) . Double staining for p53 and PCNA was also performed using an antibody against p53 in 9.5 mg/ml and PCNA, PC10 (monoclonal mouse antibody; Dako Corporation) in the concentration of 19.3 mg/ml, according to our previous study (Ebina et al., 1994) . For Mdm2 detection we used a mouse monoclonal antibody against the human protein from Oncogene Science (Cambridge, MA, USA) at dilution 10 mg/ml. Optimal concentrations for each antibody were determined by pilot studies using known positive control sections (Hall et al., 1997) .
Microdissection and DNA extraction
From serially cut, dewaxed and dried sections, tumor foci corresponding to p53 positive or negative areas by immunohistochemistry, were microdissected using micropipet tips and collected into separate tubes. Specimens were digested with 0.5 ml of protein lysis buer (50 mM Tris, 1 mM EDTA, 0.5% Tween 20, pH 8.5) containing 0.4 mg/ml proteinase K, for 3 h at 558C. The reaction was stopped by heating at 948C for 7 min. In addition, genomic DNA was extracted from freshly grown cell lines to be used in the standard PCR.
PCR/SSCP analysis and DNA sequencing
A Perkin-Elmer 9600 Thermocycler (Perkin-Elmer Cetus, Norwalk, CT, USA) was used to amplify the DNA samples. The DNA extracted from the various tumor areas was used for PCR/single-strand conformation polymorphism (SSCP) analysis spanning p53 exons 4 through 9 Hall et al., 1997) . The exons showing shifted bands were cloned into a pCRII vector (Invitrogen, San Diego, CA, USA), and puri®ed through Qiagen Mini Columns (Qiagen Inc., Chatsworth, CA, USA). DNA sequencing was performed using a dsDNA cycle sequencing system (Gibco ± BRL, Gaithersburg, MD, USA) and primers end-labeled with g- 
Design of the primers and testing them in standard PCR
Following the double mismatch approach (Cha et al., 1992) , we designed three to six pairs of mutant speci®c primers (Muts) for the cases with single base-pair mutations in p53, resulting in one base-pair mismatch with mutant p53 and two base-pair mismatches with wild-type. Likewise, speci®c primers for wild-type p53 (Wts) were synthesized which had one base-pair mismatch with wild-type and two base-pair mismatches with the mutant p53. Common primers (Com) had no mismatch with wild-type, but one base-pair mismatch with mutant p53, and, consequently, ampli®ed both wild and mutant p53.
In the ®rst case ( Figure 1a ) the sense primer of Muts was set within intron 3 (11999 ± 12020; 5'-TGCTCTTTTCACC-CATCTACAG-3') while the antisense primer (5'-GAAC-CATTGTTCAATATCGTCCAA-3') was set to detect the mutation (TCG) in codon 47. They had one base-pair mismatch with mutant p53 and two base-pair mismatch with Topography of mutant p53 in non-small cell lung cancer M Ebina et al wild-type p53. The wild-type speci®c (WTs) primers set within exon 4 (sense; 5'-GATGATTTGATGCTGTCCT-3', antisense; 5'-CAGGGGCCGCCGGTGTAGGAG-3'), which had one base-pair mismatch with wild-type p53 and two base-pair mismatch with mutant p53 were designed for detecting exclusively the wild-type (CCG) sequence ( Figure  2a ). Common (Com) primers set in intron 3 (sense; 5'-TGCTCTTTTCACCCATCTACAG-3') and in exon 4 (antisense; 5'-GAACCATTGTTCAATATCGTCCGG-3'), were set as a positive control, with no mismatch with wild p53 and one base-pair mismatch with the mutant p53 (Figure 2a) . The optimal PCR condition for each primer set was tested as shown in Figure 2b . The optimal PCR-mixture composition selected for these three dierent pairs of primers (WTs, Muts, and Com) was 2.5 mM Mg 2+ , pH 10.0, with an annealing temperature of 618C. The sizes of the products were 136 basepairs by Wts, and 88 base-pairs by Muts primers (Figure 2c ).
In the second case ( Figure 1b ) the wild-type speci®c primers (Wts, sense in exon 8; 5'-GAGGTGCGTGTTTGTG-CCCG-3' and antisense in intron 9; 5'-CAGGGGCCGCCG-GTGTAGGAG-3') ampli®ed their speci®c target sequences yielding a 133 base-pair product (Figure 2d ). The sense primer of the mutant speci®c (Muts), and common (Com) primers was set in intron 7 (14424 ± 14447, 5'-CTTGCTTCT-CTTTTCCTATCCTGA-3'), and antisense primers were set in exon 8 with the dierent sequence at the end of three prime (Muts; 5'-TGCGCCGGTCTCTCCCAGGGAAC-3' and 5'-TGCGCCGGTCTCTCCCAGGGACA-3') ( Figure  2d ). The optimal reaction required a PCR mixture containing 1.5 mM Mg 2+ at pH 10.0, and an annealing temperature of 608C ( Figure 2e) .
As the third case was found to have a nine base-pair duplication in exon 5 (Figure 1c) , only two sets of primers were designed: (i) mutant speci®c primers (Muts), for amplifying mutant p53 only and (ii) common primers (Com) which ampli®ed both wild and mutant p53. As shown in Figure 2f , both sense and antisense primers of Muts were set within exon 5 (5'-TACTCCCCTGCCCTCAAC-3' and 5'-CTGTGACTGCTTGTACTG-3', respectively), which were also used to amplify mutant cDNA during in situ RT ± PCR. The common primers (Com) were also set within exon 5 (sense; 5'-CGCGCCATGGCCATCTACAAG-3', antisense; 5'-CTCATGGTGGGGGCAGCGCCT-3'), and the PCR products were 69 bp in wild-type p53 and 78 bp in this mutant p53 sequence with nine base-pair duplication. Standard PCR with these primers demonstrated their speci®city by yielding 69 and 78 bp products for the Com and Muts primers, respectively (Figure 2g ). Optimal PCR conditions were 1.5 mM Mg 2+ , pH 10.0 and an annealing temperature of 608C.
All primers were synthesized in-house using a MilliGen 8700 DNA synthesizer (Millipore, Marlborough, MA, USA). As indicated, the speci®city of the designed primers was tested by standard PCR, using human genomic DNA, DNA extracted from cell lines, or cloned DNA fragments. The MgCl2 concentration and pH of the PCR mixture was selected using PCR Optimizer Kit (Invitrogen, San Diego, CA, USA). The appropriate annealing temperature was selected from a range between 51 and 638C and settled for each set of primers to avoid the possible eect by dierent annealing temperature (Figure 2b) . The other conditions were kept identical for all reactions in the three tumors: denaturing at 948C for 15 s, annealing time for 30 s and extension at 728C for 30 s for 30 cycles, with an initial denaturing step at 948C for 1 m. In order to perform`hot start' in our PCR reaction (Nuovo, 1994) , we applied the neutralizing antibody technique (MartõÂ nez et al., 1995) using TaqStart antibody (Clontech Laboratories, Palo Alto, CA, USA).
In situ PCR Direct in situ PCR was performed as previously described with minor modi®cations (MartõÂ nez et al., 1995) . Brie¯y, dried dewaxed sections on DNaseRNase free glass slides were incubated with protein lysis buer (0.1 M Tris, 50 mM EDTA, pH 8) containing 20 mg/ml Proteinase K for 20 min at 378C. The reaction was stopped with PBS containing 0.1 M glycine for 5 min. After thoroughly washing with PBS, 75 ml of the PCR optimal solution of, containing digoxigenin-11-[2'-deoxy-uridine-5']-triphosphate (DIG-11-dUTP; Boehringer Mannheim, Indianapolis, IN, USA) was added and the PCR reaction was carried out for 20 ± 35 cycles in an Omni Slide System thermocycler (Hybaid, Hollobrook, NJ, USA). After washing twice in 0.16SSC for 20 min each at 458C, the incorporated PCR fragments were visualized by the digoxigenin detection kit (Boehringer Mannheim).
In situ RT ± PCR After Proteinase K (10 mg/ml) digestion at 378C for 15 min, reverse transcription was performed using the SuperScript Preampli®cation System (Gibco ± BRL) following the manufacturer's speci®cations. In brief, 70 ml DEPC-treated water containing 2.5 mg oligo(dT) 12 ± 18 was added to each section, covered with para®lm, and incubated for 10 min at 708C. After 1 min on ice, another solution (30 ml) including reverse transcriptase (100 U/section) was added to the sections, covered with para®lm, and the slides were incubated at 428C for 50 min, followed by 15 min at 708C. After thorough washes, direct in situ PCR was performed after this reverse transcription reaction using mutation speci®c primers as described before.
Controls included substituting the primers by H 2 O in the PCR reaction and omission of the reverse transcription in the case of mRNA.
Southern blotting analysis
After in situ PCR using mutant speci®c primers without DIG-11-dUTP, whole sections were scraped from the slide into tubes, and ampli®ed DNA fragments were extracted by ethanol precipitation and loaded onto a 2% agarose gel. The separated fragments were transferred to nitrocellulose membranes, Nytran Plus (Schleicher & Schnell, Keene, NH, USA), hybridized with the probes, corresponding to the mutant DNAs labeled with a-32 P-dCTP using Prime It (Strategene, La Jolla, CA, USA).
